Comparing of Checkpoint Therapeutics Inc. (CKPT) and Halozyme Therapeutics Inc. (NASDAQ:HALO)

As Biotechnology companies, Checkpoint Therapeutics Inc. (NASDAQ:CKPT) and Halozyme Therapeutics Inc. (NASDAQ:HALO) are our subject to compare. And more specifically their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Checkpoint Therapeutics Inc. 1 0.00 27.15M -0.85 0.00
Halozyme Therapeutics Inc. 19 -1.58 144.55M -0.27 0.00

Table 1 demonstrates Checkpoint Therapeutics Inc. and Halozyme Therapeutics Inc.’s gross revenue, earnings per share and valuation.


Table 2 provides us Checkpoint Therapeutics Inc. and Halozyme Therapeutics Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Checkpoint Therapeutics Inc. 1,920,628,183.36% -340% -158.3%
Halozyme Therapeutics Inc. 772,994,652.41% -15.8% -9.6%


1.8 and 1.8 are the respective Current Ratio and a Quick Ratio of Checkpoint Therapeutics Inc. Its rival Halozyme Therapeutics Inc.’s Current and Quick Ratios are 3.2 and 2.8 respectively. Halozyme Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than Checkpoint Therapeutics Inc.

Analyst Recommendations

In next table is delivered Checkpoint Therapeutics Inc. and Halozyme Therapeutics Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Checkpoint Therapeutics Inc. 0 0 0 0.00
Halozyme Therapeutics Inc. 0 1 4 2.80

Competitively the consensus price target of Halozyme Therapeutics Inc. is $22.8, which is potential 12.70% upside.

Insider and Institutional Ownership

Institutional investors held 12.4% of Checkpoint Therapeutics Inc. shares and 87.2% of Halozyme Therapeutics Inc. shares. About 1.3% of Checkpoint Therapeutics Inc.’s share are held by insiders. Insiders Competitively, held 0.1% of Halozyme Therapeutics Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Checkpoint Therapeutics Inc. -4.55% -33.33% -53.51% -72.79% -44.49% -30.77%
Halozyme Therapeutics Inc. -1.19% 12.57% 20.73% 23.85% 23.29% 30.96%

For the past year Checkpoint Therapeutics Inc. had bearish trend while Halozyme Therapeutics Inc. had bullish trend.


Halozyme Therapeutics Inc. beats Checkpoint Therapeutics Inc. on 8 of the 11 factors.

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. Its pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein BRD4, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; and Genentech. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.